Astellas Pharma Inc.

First patient treated in phase 3 studies and positive Phase 2 results of roxadustat in patients with chronic kidney disease in Japan

by Rafiuzzaman Sifat - Jul 28, 2016

News Hour: Astellas Pharma Inc. (TSE:4503, “Astellas”) and FibroGen, Inc. (“FibroGen”), announced the dosing of the first patient in Phase 3 trials in Japan of roxadustat (development code: ASP1517/FG-4592) for treatment of anemia in chronic kidney...
Cytokinetics and Astellas announce option right for tirasemtiv and expansion of global collaboration for ck-2127107 in als

by Rafiuzzaman Sifat - Jul 28, 2016

News Hour: Cytokinetics, Inc. (Nasdaq: CYTK, “Cytokinetics”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) announced that Cytokinetics and Astellas have expanded their collaboration in skeletal muscle activators to include amyotrophic lateral sclerosis (ALS). Through this expansion,...
Astellas and medivation initiate Phase III trial of enzalutamide in patients with triple-negative breast cancer

by Rafiuzzaman Sifat - Jul 28, 2016

News Hour: Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) announced plans to commence a Phase III clinical trial to investigate the use of enzalutamide for the treatment of triple-negative breast cancer (TNBC). The...

First patient treated in phase 3 studies and positive Phase 2 results of roxadustat in patients with chronic kidney disease in Japan